{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T17:17:07Z","timestamp":1762017427770},"reference-count":25,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2013,3,7]],"date-time":"2013-03-07T00:00:00Z","timestamp":1362614400000},"content-version":"vor","delay-in-days":1010,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2010,6]]},"abstract":"<jats:p>Sergliflozin, the active entity of sergliflozin etabonate, is a selective inhibitor of the sodium\u2010dependent glucose cotransporter\u20102 in the renal tubule. The pharmacokinetics and pharmacodynamics of sergliflozin were examined during administration of sergliflozin etabonate (500 or 1000 mg) or placebo 3 times daily (tid) for 14 days in healthy overweight or obese human volunteers (n = 18). At the doses tested, sergliflozin showed less than dose\u2010proportional pharmacokinetic characteristics. Mean half\u2010life of the active entity was approximately 2 hours; there was no evidence of drug accumulation. Sergliflozin etabonate produced rapid and sustained suppression of renal glucose reabsorption, resulting in a dose\u2010related glucosuria, and a transient increase in urinary electrolyte and fluid loss; plasma glucose, insulin, and electrolyte levels were unchanged. Sergliflozin etabonate produced a rapid, dose\u2010related reduction in body weight (mean changes of \u22120.09, \u22121.55, and \u22121.74 kg from baseline to day 15 with placebo, sergliflozin etabonate 500 mg, and sergliflozin etabonate 1000 mg, respectively), apparently through increased urinary calorie loss rather than through osmotic diuresis. Sergliflozin etabonate 500 or 1000 mg tid was generally well tolerated; no clinically significant adverse events were identified. Renal function (creatinine clearance) was not affected by sergliflozin etabonate, although urinary microalbumin, N\u2010acetyl\u2010beta\u2010D\u2010glucosaminidase, and \u03b2<jats:sub>2<\/jats:sub>\u2010microglobulin levels tended to increase.<\/jats:p>","DOI":"10.1177\/0091270009352185","type":"journal-article","created":{"date-parts":[[2010,3,4]],"date-time":"2010-03-04T03:44:45Z","timestamp":1267674285000},"page":"636-646","source":"Crossref","is-referenced-by-count":37,"title":["Multiple\u2010Dose Pharmacokinetics and Pharmacodynamics of Sergliflozin Etabonate, a Novel Inhibitor of Glucose Reabsorption, in Healthy Overweight and Obese Subjects: A Randomized Double\u2010Blind Study"],"prefix":"10.1002","volume":"50","author":[{"given":"Elizabeth K.","family":"Hussey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert L.","family":"Dobbins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randall R.","family":"Stoltz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy L.","family":"Stockman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin L.","family":"O'Connor\u2010Semmes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Kapur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon C.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debbi","family":"Layko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek J. R.","family":"Nunez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,7]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-141-6-200409210-00007"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.321.7258.405"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.8.2067"},{"key":"e_1_2_5_6_2","first-page":"F459","article-title":"Cloning of a human kidney cDNA with similarity to the sodium\u2010glucose cotransporter","volume":"263","author":"Wells RG","year":"1992","journal-title":"Am J Physiol"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116972"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.1996.270.4.G541"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.2001.280.1.F10"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00439-002-0820-5"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5000194"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.15.11.1531"},{"issue":"4","key":"e_1_2_5_13_2","first-page":"285","article-title":"Sodium\u2010glucose cotransporter inhibitors for diabetes","volume":"8","author":"Isaji M.","year":"2007","journal-title":"Curr Opin Investig Drugs"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.106.110296"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2009.03.007"},{"key":"e_1_2_5_16_2","article-title":"The single\u2010dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and subjects with type 2 diabetes mellitus","author":"Hussey E","journal-title":"J Clin Pharmacol"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1262-3636(07)70190-8"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.328"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.50.3.609"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.20.11.1744"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1463-1326.2000.00049.x"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0802215"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00861555"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.22.11.1882"},{"key":"e_1_2_5_25_2","first-page":"79","article-title":"Urinary IgG excretion as a prognostic factor in idiopathic membranous nephropathy","volume":"48","author":"Reichert LJ","year":"1997","journal-title":"Clin Nephrol"},{"issue":"1","key":"e_1_2_5_26_2","first-page":"A128","article-title":"Dose regimen optimization for a novel therapeutic drug (SGLT2 inhibitor) using a physiological pharmacokinetic\u2010pharmacodynamic model incorporating both human and in vitro data","volume":"56","author":"O'Connor\u2010Semmes RL","year":"2007","journal-title":"Diabetes"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F0091270009352185","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/0091270009352185","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T20:06:30Z","timestamp":1698955590000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1177\/0091270009352185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["10.1177\/0091270009352185"],"URL":"https:\/\/doi.org\/10.1177\/0091270009352185","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}